OBJECTWAY
16.5.2024 14:51:39 CEST | Business Wire | Press release
Objectway, global FinTech provider of as-a-service software to banks, wealth and asset managers, has been working with Ramsey Crookall to progressively support the firm’s organic business growth and expansion into other areas of the market over recent years.
Ramsey Crookall is the Isle of Man’s longest established independent stockbroking and award-winning investment firm, providing a full range of bespoke stockbroking and wealth management services to private and institutional clients, trusts and pension funds predominantly in the UK, the Isle of Man and South Africa.
Its partnership with Objectway has enabled Ramsey Crookall to evolve from a traditional values stockbroker to a progressive, digitally-enabled multi-service investment management firm. This evolution has been supported by Objectway’s modular solution providing the firm with a scalable front-to-back technology platform.
This long-term strategic collaboration began with the provision of Objectway’s Investment Administration, enabling the firm to streamline and manage the core back-office operations more efficiently, whilst freeing up resources to deliver scale and enabling them to differentiate their business in the market.
In the second phase, Objectway’s Portfolio Management enhanced the firm’s ability to deliver efficient management and execution of their investment strategy for their Investment Managers and Dealers.
In a third phase, Objectway integrated these capabilities with the new client portal to enable an omni-channel and streamlined digital investment experience for Ramsey’s clients. This improved client visibility and significantly digitalised their client touch points without losing the personal touch that their business has so successfully built throughout its long history.
The current phase is to introduce enhanced capabilities for client lifecycle management, a more efficient client onboarding process and client Apps to provide clients with the choice for even greater flexibility and digital interaction, by deploying Objectway’s Client Management solutions.
“As a trusted family business offering a bespoke service, we’re constantly evolving to meet our clients’ needs and expectations. As such, we wanted to rely on a partner who shared the same future-focused vision, who could enable a steady technology evolution for the business,” said Joanna Crookall, CEO at Ramsey Crookall. “Our long-standing relationship with Objectway has enabled us to expand our services seamlessly into new territories, such as South Africa and to develop new services, such as, our discretionary model service aimed at the next generation of investors and our trading/custody services for professional clients. Over the years we have valued their ability to support our business differentiation and expansion at a pace that suited us.”
“We’re proud to have been partnering with Ramsey Crookall contributing to their success. By moving entirely to our SaaS solution, we’ve been able to meet their objectives for efficiency, cost effectiveness, scalability and timely delivery. Ramsey Crookall appreciated the value and benefits of a fully integrated, fully managed and digitally enabled solution from a single, trusted partner. We look forward to delivering value to their business for many years to come” commented Alexander Cassar, Objectway’s Chief Business Development Officer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515189528/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
